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Journal of Vascular Surgery between 2010 and 2012, was performed and
included all 27 PRISMA items. For each article, two scores were calculated:
“Points,” where maximally “72” points could be scored per article; and
“Ratio,” where a point fraction could be scored for each PRISMA item.
Results are means 6 standard deviation.
Results: Of 1820 articles totally, 37 were MAs and 18 SRs. From
2010 to 2012, a signiﬁcant decrease in the number of published random-
ized controlled trials and increase in MAs was observed (P ¼ .047),
while SRs remained stable. The average “Points” score for MAs was 45
6 11 and “Ratio” score 17 6 4.7. For SRs, the average “Points”
score was 33 6 11 and “Ratio” score 11 6 3.6. Although statistically
insigniﬁcant, a trend towards improved reporting over time was observed
(P ¼ .271).
Conclusions: As the number of randomized controlled trials in
vascular surgery continues to diminish, the role of SRs and MAs in providing
evidence-based information becomes more important. However, the clarity
and transparency of SRs and MAs are not optimal. Improved conduct and
reporting will be important to advance health care decision-making and
better identify targets for future research.Fig.
Table. Multivariable predictors of ASC complications
Hazard
ratio
95% Conﬁdence
interval P value
Age – – –
<65 years 1.65 0.81-3.33 .167
65-74 years 2.37 1.27-4.42 .006
Preoperative warfarin use 2.46 1.44-4.19 .001
Vascular closure devices vs
manual compression
0.64 0.37-1.13 .124
Post- vs pre-RUS period 0.50 0.29-0.86 .012
ASC, Access-site-related complications; RUS, routine ultrasound-guided.Factors Associated with Femoral Artery Access Site Hematoma
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School of Public Health, Boston, MassObjectives: Local vascular complications have a reported incidence of
1% to 7% and are the most frequent adverse outcome of femoral arterial
access. This study aimed to identify variables associated with groin hema-
toma after peripheral vascular intervention (PVI).
Methods: The Vascular Study Group of New England (VSGNE)
database (2010-2012) was queried to identify the complication of postpro-
cedural groin hematoma after 4930 PVIs performed via femoral arterial
access. Hematoma (including pseudoaneurysms) was deﬁned as minor
(requiring compression or observation), moderate (requiring transfusion
or thrombin injection), and major (requiring operation). Associated vari-
ables were identiﬁed using multivariable logistic regression models.
Results: The overall post-procedural groin hematoma rate after PVI
was 4.7%, and the rate of moderate/major hematoma was 0.9%. Groin
hematoma had no effect on mortality, but was associated with increased
mean hospital length of stay (3.3 days vs 2 days; P < .001). Independent
predictors of hematoma included: age>80 years (odds ratio [OR] 2.16,
95% CI, 1.04-4.52; P ¼ .04), female gender (OR, 1.81; 95% CI, 1.37-
2.40; P < .001), bilateral femoral access (OR, 1.61; 95% CI, 1.16-2.24;
P ¼ .005), and sheath size >6 French (OR, 1.61; 95% CI, 1.18-2.22;
P ¼ .003). Use of closure devices was protective against hematoma (OR,
0.48; 95% CI, 0.35-0.66; P < .001), as was performance of PVI in the
second half of the academic year (January through June; OR, 0.71; 95%
CI, 0.54-0.93; P < .02). Neither ultrasound guidance nor body mass index
had any effect on hematoma rates.
Conclusions: Many important risk factors that predict hematoma
formation after femoral arterial access for PVI are not modiﬁable. However,
the appropriate use of smaller sheaths as well as closure devices may poten-
tially protect against the complication of hematoma, and may provide
a quality improvement opportunity to decrease patient morbidity as well
as hospital resource utilization.Predictors of Access-Site-Related Complications After Lower Extremity
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Objectives: Though well described in the cardiology literature, less is
known about risks for access-site-related complications (ASC) following
percutaneous lower extremity revascularization. We also sought to eval-
uate the beneﬁt of routine ultrasound-guided access (RUS) in decreasing
ASC.
Methods: We reviewed all percutaneous revascularizations (percuta-
neous transluminal. angioplasty or stent) performed for lower extremity
atherosclerosis at our institution from 2002 to 2012. RUS began in October
2007. Primary outcome was any ASC (bleeding, groin or retroperitoneal
[RP] hematoma, vessel rupture, or thrombosis). Multivariable logistic
regression was used to determine predictors of ASC.
Results: A total of 1419 punctures were performed on 925 patients
(43% women; median age, 69 years [interquartile range, 60-78 years])
for claudication (30%), critical limb ischemia (58%), or other (12%) using
4- to 8-Fr sheaths. Seventy-six ASC occurred (5.4%): 15 instances of
bleeding, 41 groin and eight RP hematoma, two artery ruptures, nine
pseudoaneurysms, and one thrombosis. Computed tomography evalua-
tion was done in 13, thrombin injection in nine, and operative repair
in 20 patients. ASC were more common before RUS (7.6% vs 4.5%; P
¼ .026). Multivariable predictors of ASC were older age, preoperative
warfarin use, and procedure performance before RUS (Table). Vascular
closure devices were not associated with ASC rates but when
attempted, failures were associated with a higher ASC rate (15% vs 4%;
P ¼ .006).
Conclusions: RUS has decreased ASC in recent years but vascular
closure devices have not demonstrated a signiﬁcant impact. Particular care
